Signup is free and no credit card is required.

HomeVACC:NASDAQ

Vaccitech plc

$5.00USD

10.20%+0.51

0.00

NASDAQ

Healthcare

Biotechnology

Year range

1.64 - 5.10

Market cap

$192.73M USD

Avg Volume

731.88K

P/E ratio TTM

-0.57

Dividend yield TTM

0.00%

Primary exchange

NASDAQ Global Market

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious disea... Read more

CEO

Mr. William J. Enright MBA

Employees

Website

vaccitech.co.uk

Country

IPO Date

Apr 30, 2021

Headquarters

The SchrOedinger Building, Oxford

Phone

+44 1865 818 808

Advanced Financial Analysis

Powerful insights without barriers. No credit card or login required.

Global Stocks, ETFs & Fund Coverage

Unlimited Monthly Prompts

Chat with Voyager: AI Chatbot

Unlimited Monthly Company Reports

5 Portfolios with Unlimited Holdings

Watchlist Functionality

30 Years of Financial Data

Analyst Estimates & Ratings

Priority Support

Free access to financial analysis tools. No credit card required.

NumbersChart Mode

Valuemetrix

Enter your information to create your account

Already have an account?

By contining, you agree to our Terms of Service and Privacy Policy.

1Main Ratios

Key financial ratios and metrics that provide insights into a company’s valuation, solvency, efficiency, and growth.

valuation

P/E:

-0.57

P/B:

0.32

P/S:

2.51

P/FCF:

-1.46

EV/EBITDA:

80.00

EV/Sales:

6.28

PEG Ratio:

0.10

Dividend Yield:

0.00%

DPS:

$0.00

solvency

EV:

$94.08M

Debt to Equity:

0.10

Interest Coverage:

-1804.71

Cashflow to Debt:

-2.41

Debt Ratio:

0.19

Long Term Debt to Capitalization:

0.08

Current Ratio:

9.18

Cash Ratio:

8.28

efficiency

Return on Equity:

-46.48%

Return on Capital Employed:

-38.86%

Operating Profit Margin:

-337.58%

Net Profit Margin:

-435.85%

Asset Turnover Ratio:

0.09

Inventory Turnover Ratio:

0.00

Receivables Turnover Ratio:

0.00

growth CAGR

Revenue Growth (1Y):

Net Income Growth (1Y):

Revenue Growth Per Share (5Y):

Net Income Growth Per Share (5Y):

Operating Cashflow Growth (1Y):

Was this helpful?

2Valuation

3Future Growth

This section provides an overview of the future growth of the company.

3.1

Future Estimates

4Past Earnings Performance

5Recent News and Updates for VACC

7Earning Call Insights VACC

Period

Held On

Was this helpful?

Ownership

Who are the major shareholders and have insiders been buying or selling?

8.1

Recent Insider Transactions

NASDAQ:VACC Recent Insider Transactions by Companies or Individuals

Was this helpful?

8.2

Vaccitech plc

Advanced Financial Analysis

1Main Ratios

Was this helpful?

2Valuation

3Future Growth

Future Estimates

4Past Earnings Performance

5Recent News and Updates for VACC

7Earning Call Insights VACC

Was this helpful?

Ownership

Recent Insider Transactions

Was this helpful?

Insider Trading Volume

9Financials of VACC

10Filings of VACC

Was this helpful?

6Financial Health for Vaccitech plc

Financial Strength Ratios

Liquidity

Leverage

Financial Strength

Financial Strength Historical

Was this helpful?

Financial Position Analysis

Debt to Equity History and Analysis

Was this helpful?